Vulpes Investment Management invests in companies with cutting-edge technologies in the life sciences sector.
Portfolio
2
companies
Oxford Endovascular
Oxford Endovascular develops origami-inspired medical devices for brain aneurysm treatment.
Veremark
Veremark operates a digital platform for global background screening and employee conduct risk management.
Martin Diggle
Portfolio Manager, Life Sciences
Parkwalk Advisors spearheaded the round to help the medical technology company prepare for human trials.
"With the support of our investors, we are on the cusp of revolutionising brain aneurysm treatment. Our team is dedicated to working with regulators, medical professionals, and industry experts to bring this product to market and address a condition impacting countless individuals worldwide."
The pre-series b round was led by Samaipata and Stage 2 Capital to support client acquisition and technology development.
"With the cost of failed hires estimated to be three times their annual salary, Veremark’s efficient solution to background screening is helping businesses make fully informed hiring decisions. Despite a global slow down in recruitment, the company has continued to deliver exceptional growth due to the value it brings to customers. We are excited to continue backing Veremark’s remarkable growth journey as it continues to redefine workplace compliance and screening."
The Series A round was led by Stage 2 Capital with participation from Samaipata and existing investors.
"Effective pre-employment screening and candidate vetting are critical considerations for business operations, compliance, and risk management. Yet, around the world, these processes are highly manual and often delayed, inaccurate, or incomplete."
The pre-employment screening platform raised £2m in follow-on funding to scale its credential verification services.
"Veremark’s aim is to help companies hire with greater confidence. Our platform is about bringing speed, simplicity and security to the hiring market. It doesn’t matter whether you are hiring in Bermondsey, Bangalore or Baltimore – we enable companies to check the claims and credentials of those they are looking to bring onboard into their companies. We see this round as an initial stepping stone in the start of transforming the overall ‘Trust’ market and build a new category around credential management to drive greater efficiency in the hiring market and beyond"
The financing round was led by Vulpes Investment Management with backing from existing investors to fund first in-human data acquisition.
"The current device market for brain aneurysms is valued at well over $1bn and is growing rapidly year-on-year. One of the biggest challenges when it comes to treating neurovascular disease is having devices with high efficacy whilst minimising adverse events. Studies show that often multiple attempts are made to place treatment devices, as they often have challenges of landing accurately, opening and maintaining position. This can lead to adverse events and multiple devices being used. Procedures typically cost over $50,000 to treat a brain aneurysm and a next generation flow diverter overcoming unmet needs, offers the chance for more effective, safer and cost effective treatments as well as allowing many more patients to benefit. We plan to use this funding to bring Oxford Endovascular’s ground-breaking technology to the next stage and gain clinical data from human studies."
